Corcept Therapeutics (HAM:HTD) Current Deferred Revenue: €29.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:HTD Corcept Therapeutics Inc HAM:HTD
88 GF Score
Price €79.10
GF Value €58.27
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Current Deferred Revenue?

Corcept Therapeutics HAM:HTD -2.94% 88 Current Deferred Revenue is €29.0 Mil as of Mar. 2026. GuruFocus rates HAM:HTD with a GF Score™ of 88/100 and a GF Value™ of €58.27. The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Corcept Therapeutics's current deferred revenue for the quarter that ended in Mar. 2026 was €29.0 Mil.

Corcept Therapeutics Current Deferred Revenue Related Terms

Corcept Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Current Deferred Revenue Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.89 10.48 16.94 39.71 30.47

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.92 44.10 45.44 30.47 29.03
HAM:HTD
88GF Score
Corcept Therapeutics Inc HAM:HTD
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €29.0 Mil mean?
Corcept Therapeutics (HAM:HTD) has a Current Deferred Revenue of €29.0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Current Deferred Revenue too high?
Corcept Therapeutics' current Current Deferred Revenue is €29.0 Mil. Overall, Corcept Therapeutics has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Current Deferred Revenue compare to PRAX and IBRX?
Corcept Therapeutics' Current Deferred Revenue of €29.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Current Deferred Revenue is €29.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Current Deferred Revenue of €29.0 Mil. The stock's GF Value™ is €58.27, compared to a current price of €79.10 — trading 35.7% above its estimated fair value. The current Current Deferred Revenue is €29.0 Mil. Corcept Therapeutics' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Current Deferred Revenue is €29.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €79.10 is trading 35.7% above its estimated GF Value™ of €58.27.

Key valuation signals for HAM:HTD:

  • Current Deferred Revenue: €29.0 Mil
  • GF Value™: €58.27 vs. price of €79.10 (35.7% above fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
88GF Score

Get the complete analysis for HAM:HTD

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€79.10
Price
€58.27
GF Value